Trials / Completed
CompletedNCT07429032
The Effect of AMG 133 on Gastric Emptying
A Phase 1, Randomized, Double Blind, Multiple Dose, Placebo-controlled, Parallel Group Study to Evaluate the Impact of AMG 133 on Gastric Emptying in Participants Living With Overweight or Obesity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the trial is to evaluate the effect of AMG 133 versus placebo on acetaminophen pharmacokinetics (PK), a marker for gastric emptying, in participants living with overweight or obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 133 | AMG 133 will be administered SC. |
| DRUG | Placebo | Placebo will be administered SC. |
| DRUG | Acetaminophen | Acetaminophen will be administered orally. |
Timeline
- Start date
- 2025-04-17
- Primary completion
- 2025-11-26
- Completion
- 2025-11-26
- First posted
- 2026-02-24
- Last updated
- 2026-02-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07429032. Inclusion in this directory is not an endorsement.